Recent evidence indicates that inhibition of SGLT1 and SGLT2 may offer therapeutic advantages over existing treatments for patients with T2DM, potentially attributable to the renal and cardiovascular protective effects associated with SGLT1 inhibition [204]. This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.